Research Analysts’ Recent Ratings Updates for Alpha Tau Medical (DRTS)

Several brokerages have updated their recommendations and price targets on shares of Alpha Tau Medical (NASDAQ: DRTS) in the last few weeks:

  • 5/20/2026 – Alpha Tau Medical had its “buy” rating reaffirmed by HC Wainwright. They now have a $15.00 price target on the stock.
  • 5/19/2026 – Alpha Tau Medical had its price target raised by Piper Sandler from $5.00 to $8.00. They now have a “neutral” rating on the stock.
  • 5/12/2026 – Alpha Tau Medical had its price target raised by LADENBURG THALM/SH SH from $12.00 to $14.00. They now have a “buy” rating on the stock.
  • 5/12/2026 – Alpha Tau Medical had its price target raised by HC Wainwright from $12.00 to $15.00. They now have a “buy” rating on the stock.
  • 4/20/2026 – Alpha Tau Medical had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.

Featured Articles

Receive News & Ratings for Alpha Tau Medical Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical Ltd and related companies with MarketBeat.com's FREE daily email newsletter.